Clinical Trials
Phase I ASTEROID Trial: Tolinapant Combined With Pembrolizumab in Advanced Solid Tumors
Tiu et alNature communications
In the phase I ASTEROID trial (NCT05082259), investigators evaluated the safety, pharmacokinetics, and anti-tumor activity of tolinapant (ASTX660)—a non-peptidomimetic antagonist of cIAP1, cIAP2, and XIAP—in combination with pembrolizumab among patients with advanced solid tumors. By targeting inhibitor of apoptosis (IAP) proteins that suppress RIPK1-driven immunogenic cell death, tolinapant is designed to lower the tumor necrosis factor (TNF) cytotoxicity threshold and sensitize tumors to T cell-mediated cytotoxicity.
The combination was well tolerated and demonstrated early evidence of clinical efficacy. The regimen yielded an overall response rate of 33%, with anti-tumor activity observed in tumor types historically refractory to immune checkpoint blockade, including ER⁺ breast cancer.
Integrated translational analyses revealed distinct immunologic correlates: patient responses were characterized by a TNF- and IFN-enriched inflammatory tumor microenvironment, elevated tumor antigenicity, and broadened T-cell receptor (TCR) clonal diversity. Conversely, disease resistance was associated with an immunosuppressive niche enriched for CCR4-, CCR6-, CCR7-, and CCR8-driven tumor-associated macrophages (TAMs) and regulatory T cells (Tregs). These findings provide clinical proof-of-concept that dual IAP and PD-1 blockade sensitize tumors, while identifying candidate biomarkers to guide patient stratification in future studies.
Key Takeaways
- Tolinapant combined with pembrolizumab achieved an overall response rate of 33% in advanced solid tumors, including responses in ER⁺ breast cancers typically resistant to immune checkpoint blockade.
- Response was associated with a TNF/IFN-enriched inflammatory tumor microenvironment, increased tumor antigenicity, and enhanced TCR clonal diversity, whereas resistance correlated with a CCR4/6/7/8-driven TAM/Treg-dominant niche.
Read the original sourceNature communications
